Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04764344 · ClinicalTrials.gov registry record · Phase 4
Haloperidol for the Treatment of Nausea and Vomiting in the ED
A Phase 4 study, sponsored by Western Michigan University School of Medicine.
- Completed
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
NCT04764344 is a Phase 4 study that has completed, run by Western Michigan University School of Medicine. The registered enrollment target is 60 participants.
The verdict
NCT04764344, a Phase 4 study, has completed, sponsored by Western Michigan University School of Medicine.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
Study Summary
Single center, double-blind, randomized, controlled trial in patients who present to the emergency department (ED) with a chief complaint of nausea or vomiting. A total of 300 patients age 18-55 presenting to the emergency department with chief complaint of nausea or vomiting will be enrolled from February 2021 - February 2022. Patients will be randomized and symptom levels will be recorded at 30, 60, 90, minutes. Follow-up will be performed by telephone at 24 hours.
Interventions
- DRUG Haloperidol
- DRUG Ondansetron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2021-04-01 |
| Est. Completion | 2023-05-22 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04764344
The ClinicalTrials.gov registry entry for NCT04764344 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Western Michigan University School of Medicine, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Haloperidol is the first listed.
NCT04764344 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04764344 about?
NCT04764344 is a clinical study titled "Haloperidol for the Treatment of Nausea and Vomiting in the ED". Single center, double-blind, randomized, controlled trial in patients who present to the emergency department (ED) with a chief complaint of nausea or vomiting. A total of 300 patients age 18-55 presenting to the emergency department with chief complaint of nausea or vomiting will be enrolled from F...
What is the current status of trial NCT04764344?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2021-04-01. Estimated completion is 2023-05-22.
What interventions are being tested in trial NCT04764344?
The interventions under investigation include: Haloperidol (DRUG), Ondansetron (DRUG).
Who is sponsoring clinical trial NCT04764344?
This trial is sponsored by Western Michigan University School of Medicine, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.